Beyond Hemoglobin: New Surrogate Endpoints Finding Use In Diabetes Trials
Executive Summary
CHICAGO -With diabetes studies that evaluate glycemic control receiving criticism, industry has started conducting trials utilizing alternative surrogate endpoints
You may also be interested in...
Diabetes Trials: FDA Wants Bigger Studies; Industry Suggests Counting Phase II
Industry is striking a generally positive tone in comments on FDA's draft guidance on diabetes product development, but is expressing concern about the recommendation that the size of trials should be increased
Diabetes Trials: FDA Wants Bigger Studies; Industry Suggests Counting Phase II
Industry is striking a generally positive tone in comments on FDA's draft guidance on diabetes product development, but is expressing concern about the recommendation that the size of trials should be increased
Diabetes Draft Guidance May Require Extended Trial Length, Participation
A long-awaited diabetes draft guidance from FDA may result in longer and larger clinical trials, but does not significantly alter the development landscape since it re-affirms the agency's faith in a long-used surrogate marker and the technique of post-market outcomes assessment